Cargando…

Whole-lesion ADC histogram and texture analysis in predicting recurrence of cervical cancer treated with CCRT

PURPOSE: To explore the value of whole-lesion apparent diffusion coefficient (ADC) histogram and texture analysis in predicting tumor recurrence of advanced cervical cancer treated with concurrent chemo-radiotherapy (CCRT). METHODS: 36 women with pathologically confirmed advanced cervical squamous c...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Jie, Zhu, Lijing, Zhu, Li, Xie, Li, Wang, Huanhuan, Liu, Song, Yan, Jing, Liu, Baorui, Guan, Yue, He, Jian, Ge, Yun, Zhou, Zhengyang, Yang, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696195/
https://www.ncbi.nlm.nih.gov/pubmed/29190929
http://dx.doi.org/10.18632/oncotarget.21374
Descripción
Sumario:PURPOSE: To explore the value of whole-lesion apparent diffusion coefficient (ADC) histogram and texture analysis in predicting tumor recurrence of advanced cervical cancer treated with concurrent chemo-radiotherapy (CCRT). METHODS: 36 women with pathologically confirmed advanced cervical squamous carcinomas were enrolled in this prospective study. 3.0 T pelvic MR examinations including diffusion weighted imaging (b = 0, 800 s/mm(2)) were performed before CCRT (pre-CCRT) and at the end of 2nd week of CCRT (mid-CCRT). ADC histogram and texture features were derived from the whole volume of cervical cancers. RESULTS: With a mean follow-up of 25 months (range, 11 ∼ 43), 10/36 (27.8%) patients ended with recurrence. Pre-CCRT 75th, 90th, correlation, autocorrelation and mid-CCRT ADC(mean), 10th, 25th, 50th, 75th, 90th, autocorrelation can effectively differentiate the recurrence from nonrecurrence group with area under the curve ranging from 0.742 to 0.850 (P values range, 0.001 ∼ 0.038). CONCLUSIONS: Pre- and mid-treatment whole-lesion ADC histogram and texture analysis hold great potential in predicting tumor recurrence of advanced cervical cancer treated with CCRT.